MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI – Trademark Portfolio

Entity Type: 16

MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include LILASET LIQUID LADY URINATION SET.

Baris Mah. Dr Zeki Acar Cad.

Tübitak Sitesi No:1/1/4 Gebze Kocaeli

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI have?

MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI file in?

MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI's most well-known trademarks?

MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI's registered trademark portfolio includes well-known marks such as LILASET LIQUID LADY URINATION SET. These are among 1 currently registered trademark in the portfolio.

What is MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI's trademark registration success rate?

MEDHIBIT MEDIKAL SAGLIK BILISIM LIMITED SIRKETI has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.